



PTO/SB/82 (01-06)

Approved for use through 12/31/2008. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REVOCATION OF POWER OF ATTORNEY WITH NEW POWER OF ATTORNEY AND CHANGE OF CORRESPONDENCE ADDRESS	Application Number	10/632,428-Conf. #4377
	Filing Date	August 1, 2003
	First Named Inventor	David Bebbington
	Art Unit	1624
	Examiner Name	J. H. Johnsen
	Attorney Docket Number	030682.0001-US01

I hereby revoke all previous powers of attorney given in the above-identified application.

A Power of Attorney is submitted herewith.

OR

I hereby appoint the practitioners associated with the Customer Number: 26853

Please change the correspondence address for the above-identified application to:

The address associated with
Customer Number: 26853

OR

Firm or
Individual Name Covington & Burling

Address 1201 Pennsylvania Avenue, NW

City Washington

Country USA State D.C. Zip 20004-2401

Telephone 202.662.6000 Email

I am the:

Applicant/Inventor.

Assignee of record of the entire interest. See 37 CFR 3.71.
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)

SIGNATURE of Applicant or Assignee of Record

Signature


Name Stephen Nesbitt, Chief Patent Counsel, Vertex Pharmaceuticals Incorporated

Date 11 May 2006 Telephone 617-444-6454

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.

*Total of 1 forms are submitted.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent Owner: Vertex Pharmaceuticals Incorporated

Application No./Patent
No./Control No.: 10/632,428 Filed/Issue Date: August 1, 2003

Entitled: PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS

Vertex Pharmaceuticals Incorporated, a Corporation
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. the assignee of the entire right, title, and interest; or
2. an assignee of less than the entire right, title and interest.

(The extent (by percentage) of its ownership interest is _____ %)

in the patent application/patent identified above by virtue of either:

A. An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel 013811, Frame 0894, or a true copy of the original assignment is attached.

OR

B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:

1. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.
2. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.
3. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

Additional documents in the chain of title are listed on a supplemental sheet.


As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO.
See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.



Signature



Date

Stephen Nesbitt
Printed or Typed Name

Chief Patent Counsel

Title

617-444-6454
Telephone Number